The use of low-T therapy medications, including AndroGel, Androderm and Testim, have been linked to the development of venous thromboembolism, dangerous blood clots that include deep vein thrombosis and pulmonary embolism. Thousands of men are now pursuing compensation via testosterone lawsuits that claim the manufacturers of these drugs failed to provide adequate warnings about these and other life-threatening cardiovascular side effects.
The nationwide law firm of Bernstein Liebhard LLP is now offering free legal consultations to men who may have suffered a testosterone-related thromboembolism while undergoing low-T therapy. To learn more, please call our office at (888) 994-5118.
Thromboembolism encompasses two serious blood clotting conditions:
The signs and symptoms of a pulmonary embolism:
Those associated with a deep vein thrombosis include:
Some men using low-T therapy may develop a condition called polycythemia, which occurs due to a thickening of the blood. This condition promotes the formation of thromboembolisms like deep vein thrombosis and pulmonary embolism. For some time now, the labels for prescription testosterone treatments have included a warning about venous blood clots associated with polycythemia.
In June 2014, the FDA required manufacturers to include a general warning in the drug labeling of all approved testosterone products about the risk of venous thromboembolism that may occur in the absence of polycythemia. The label change was prompted by post-marketing reports of venous thromboembolisms that had occurred in testosterone patients who were not suffering from polycythemia Read More
Legal help is available if you or a man you care about suffered a thromboembolism, deep vein thrombosis, or pulmonary embolism while undergoing low-T therapy. To learn more about the growing testosterone litigation, please call (888) 994-5118.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.